MZMeizuo Zhong

Meizuo Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meizuo Zhong has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis

    by Lanhua Tang, Shushan Zhao, Wei Liu, Nicholas F Parchim, Jin Huang, Youhong Tang, Pingping Gan, Meizuo Zhong

    Background: Circulating tumor cells (CTCs) detection has previously been used for diagnosing gastric cancer. However, the previous studies failed to make an agreement whether the detection of CTCs contributes to the diagnosis of gastric cancer. Methods: A systematic review and meta-analysis was performed to evaluate the overall accuracy of CTCs detection for diagnosing gastric cancer. PubMed, Embase and the Wanfang database were searched in all languages published up to Oct 2012. The pooled sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR and NLR, respectively), diagnostic odds ratio (DOR) and summary receiver operating characteristic (sROC) curve were calculated to evaluate the overall test performance. Results: Twenty studies were included in this systematic review and meta-analysis. The diagnostic value of CTCs detection for the gastric cancer was calculated to evaluate the overall test performance. The summary estimates of The pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio were 0.42 (95% confidence interval (CI), 0.21-0.67), 0.99 (95% CI, 0.96-1.00), 58.2 (95% CI, 9.8-345.9), 0.58 (95% CI, 0.38-0.89), and 100 (95% CI, 15–663), respectively. The summary receiver operating characteristic curve was 0.97 (95% CI, 0.95–0.98). Deek’s funnel plot asymmetry test found no evidence of study publication bias in the current study (P = 0.49). Conclusion: This systematic review suggests that CTCs detection alone cannot be recommended as a screening test for gastric cancer. However, it might be used as a noninvasive method for the confirmation of the gastric cancer diagnosis.


  • Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods

    by Yiping Liu, Liang Zeng, Shusheng Zhang, Shan Zeng, Jin Huang, Youhong Tang, Meizuo Zhong

    In the present study, we employed proteomic methods to identify and quantitate differentially expressed proteins between diffuse large B cell lymphoma (DLBCL) tissues with low and high sensitivity to combinatorial cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and explored protein networks associated with DLBCL chemoresistance to CHOP. For proteomics analysis, DLBCL tissues were collected from 14 untreated patients. Two-dimensional gel electrophoresis combined with mass spectrometry (MS) were employed to identify and quantitate differentially expressed proteins in DLBCL tissues with low or high sensitivity to CHOP chemotherapy in vitro. Nineteen proteins showing an over twofold change in the MS/MS ions score between the low sensitivity and the high sensitivity groups were identified as differentially expressed proteins and confirmed by Western blot analyses. Immunohistochemical analyses were performed in DLBCL tissue samples from 98 patients who had received four cycles of CHOP chemotherapy, which showed that expressions of the identified CHOP sensitivity biomarkers were significantly associated with therapeutic outcomes of DLBCL, suggesting that the biomarkers could be used to predict DLBCL patient outcomes. This study provides important insights into understanding the molecular basis for development of multi-drug chemoresistance in DLBCL, which may serve as a basis for identification of novel therapeutic targets and biomarkers involved in the emergence and maintenance of DLBCL resistance to CHOP.


    • 1 August 2009
      • Vol. 34  (8) , 738-43

    [Reversal effect and mechanism of lobeline on the multidrug-resistance of human breast cancer cells MCF-7/ADM].

    by Jia Chen, Liangfang Shen, Rongrong Zhou, Wei Yao, Meizuo Zhong, Zhu Hong Zhu, Shan Zeng

    To explore the reversal effect and mechanism of lobeline on the multidrug-resistance (MDR) of human breast cancer cells MCF-7/ADM. In human breast cancer cell line MCF-7/ADM, MTT assay was used to determine the cell growth inhibiting ratio of MCF-7/ADM by ADM and Fu. Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp). Taking untreated MCF-7/ADM cells as controls, flow cytometry was applied to detect the intracellular concentration of rhodamine123 in MCF-7/ADM cell intervened with lobeline of 20 micromol/L. The sensitivity of MCF-7/ADM to ADM and Fu was significantly increased by lobeline in a dose-dependent manner. The inhibitive concentration 50 (IC(50)) of ADM declined from (44.81+/-0.43) mg/L to (16.72+/-0.75) mg/L with a reversion index of 2.68. The IC(50) of Fu declined from (53.12+/-1.60) mg/L to (38.90+/-1.43) mg/L with a reversion index of 1.37. The fluorescence intensity of lobeline-treated cells was significantly higher than that of the controls, when the concentration of lobeline was more than 10 micromol/L. With fewer side effects, the reversal efficacy of 20 micromol/L lobeline was 71.6% of the classical MDR reversal agent of verapamil at the same concentration. Lobeline can reverse the MDR of MCF-7/ADM cells by inhibiting the activity of P-glycoprotein.